Abstract
Clinically significant lupus nephritis occurs in about 40% of the overall systemic lupus erythematosus population. Despite aggressive therapy with anti-inflammatory and immunosuppressive drugs, chronic kidney damage and kidney failure are common in lupus nephritis patients. Also, standard-of-care treatment regimens are associated with significant toxicity and patient morbidity. To address this problem, a number of prospective, controlled, randomized clinical trials of potential new therapies have been undertaken recently in lupus nephritis. Unfortunately, none of these trials succeeded in demonstrating better renal outcomes or less toxicity than the standard-of-care approaches. Despite these failures, all of the trials provide important insights into the clinical behavior of lupus nephritis, which can be translated into more effective management strategies. This chapter examines lessons from lupus nephritis clinical trials and uses these lessons to build a new framework for future trials of new therapeutics.
| Original language | English |
|---|---|
| Title of host publication | Systemic Lupus Erythematosus |
| Subtitle of host publication | Basic, Applied and Clinical Aspects |
| Publisher | Elsevier Inc. |
| Pages | 559-566 |
| Number of pages | 8 |
| ISBN (Electronic) | 9780128020098 |
| ISBN (Print) | 9780128019177 |
| DOIs | |
| State | Published - Jan 1 2016 |
Keywords
- Autoimmunity
- Clinical trial
- Glomerulonephritis
- Inflammation
- Kidney biopsy
- Renal response
Fingerprint
Dive into the research topics of 'Management Lessons from Clinical Trials of Kidney Disease in Systemic Lupus Erythematosus'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver